|IBBR-NIST Scientists receive MML Accolades Awards for outstanding work||
Please join us in congratulating two IBBR-NIST group members who received the Material Measurement Laboratory (MML) Award and were recognized at a ceremony with their colleagues in July. Andrea Szakal, Ph.D., a research scientist, received the Excellence in MML Safety Accolade for implementing an integrated database system and purchase request tool to support sitewide chemical inventory compliance at IBBR, and Luke Arbogast, Ph.D., a research chemist, received the MML Postdoctoral Fellow Accolade for continuing the development of Nuclear Magnetic Resonance Spectroscopy methods for atomic r
|An Extraordinary Standard: New NIST Protein Could Spur Biopharmaceutical Innovation||
GAITHERSBURG, Md.—The National Institute of Standards and Technology (NIST) has issued one of the world’s most intricate measurement standards: an exhaustively analyzed antibody protein that the biopharmaceutical industry will use to help ensure the quality of treatments across a widening range of health conditions, including cancers, autoimmune disorders and infectious diseases.
|IBBR Facility Becomes More Energy Efficient Through Optimization||
Institute for Bioscience and Biotechnology Research
Implementing OptiCx™ platform with OptimumLOOP™ nearly doubles chiller plant output while increasing reliability of the IBBR facility, a University System of Maryland joint research enterprise.
|IBBR and UMB BioMET Scientists Have Proposed a New Model To Help Solve the Mystery of How Lithium Stabilizes Moods||
New measurements may have lifted the veil on the vexingly elusive interactions through which lithium can moderate the manic highs and debilitating lows experienced by people who suffer from bipolar disorder—about 2.6 percent of Americans, according to the National Institute of Mental Health.
|IBBR Participates in Summer 2016 National Student Leadership Conference||
IBBR Participates in Summer 2016 National Student Leadership Conference
|Shape-Changing Enzyme Suggests How Small Doses of Anti-HIV Drug Might Treat Alzheimer's Disease||
Article originally written and posted by NIST News Events.
|IBBR Request for Proposals (RFP) – GMP Biomanufacturing Facility Available||
The Institute for Bioscience and Biotechnology Research (IBBR) is interested in proposals to lease a bio-manufacturing facility configured to produce biologicals under cGMP conditions in compliance with FDA requirements for phase I/II clinical trials. The facility is also equipped to perform process development research, preclinical manufacturing for material necessary for IND-enabling toxicology studies, Point of Concept (POC) studies, and process demonstration in advance of GMP manufacturing.
|Record Turnout at IBBR’s First Bio-Networking Event||
Event brings industry, academia, and government together to promote Maryland regional biotech activity
|NIST-based tBLM system nears clinical application for detection of bacterial vaginosis (BV)||
Utilizing NIST-developed materials that allow the formation of model tethered bilayer lipid membranes (tBLMs) at surfaces, researchers at the Institute of Biochemistry and the Department of Immunology and Cell Biology in Vilnius, Lithuania have functionally reconstituted an integral membrane protein toxin vaginolysin (VLY) and demonstrated the applicability of these tBLMs as a bioanalytical platform for the detection of bacterial vaginosis (BV).
|New IBBR Director Envisions Premier Biotechnology Research Institute||
COLLEGE PARK, Md. – The University of Maryland today announced the appointment of Thomas R. Fuerst, Ph.D., as the new director of the Institute for Bioscience and Biotechnology Research (IBBR). IBBR is a joint research enterprise created to enhance collaboration among the University of Maryland, College Park (UMD), the University of Maryland, Baltimore (UMB), and the National Institute of Standards and Technology (NIST) in the fields of medicine, biosciences, technology, quantitative sciences and engineering.